SHANGHAI – Hutchison Medipharma Ltd. (Chi-Med) announced its first phase III win with fruquintinib, a targeted VEGFR inhibitor studied as a third-line therapy in 416 Chinese patients with colorectal cancer (CRC). Sharing only top-line results at this time, the FRESCO study met primary and secondary endpoints of improving overall survival and progression-free survival.